



**Authors:** Rafael SANJUAN-CERVERO, Fernando J. PEÑA-MOLINA, Carlos D. NOVOA-PARRA, Nicolas H. DE LA IGLESIA, Nuria FRANCO-FERRANDO  
**Affiliation:** Hospital de Denia, Spain

## PERCEPTION

Inner sensation resulting from a material impression produced in the bodily senses



## Dupuytren's disease



Abnormal thickening of the skin in the palm of your hand at the base of your fingers

Progressive flexion of the fingers  
NO availability of extension

## Treatments

- Fasciectomy - Resection of the abnormal tissue
- Fasciectomy - Cut the abnormal tissue
- Enzimatic fasciotomy - Collagenase that "dilutes" the cord and break it
- Other treatments - Radiotherapy, splinting...

## Collagenase TREATMENT for Dupuytren's disease



## PERCEPTION OF COMPLICATIONS



3 adverse effects of the treatment

None

## OBJECTIVES

- To assess the number of complications perceived by patients
- To find the degree of concordance that this value has with that perceived by the surgeon
- To find their relationship with short-term satisfaction.

## METHODS

Prospective study.  
Complications - Linkert scale 4 points  
Satisfaction - Linkert scale 5 points  
Change in clinical status - Brief-MHQ  
Assistance Satisfaction - PEM (1<sup>st</sup> part)

Complication	Definition	For me, this complication was			
		Serious	Moderate	Mild	Insignificant
Local pain	Pain at injection site (hand)	1	2	3	4
Arm pain	Any other type of pain	1	2	3	4
Hematoma	Bruising, skin discoloration, blister	1	2	3	4
Skin disruption	Any type of skin wound	1	2	3	4
Allergic reaction	Intense itching or palpable painful lump in armpit or elbow	1	2	3	4

## RESULTS

- ✓ 85 Treatments
- ✓ Number of complications
  - ✓ 1.48 mean seen by patients
  - ✓ 2.18 mean seen by the surgeon
- ✓ BriefMHQ → 12.1 SD 10.8 points Improvement before-after treatment (P<0.001)
- ✓ SATISFACTION
  - ✓ 88% + procedure
  - ✓ 89% repeat treatment

- ✓ **NO** concordance with what was perceived as a secondary effect with the surgeon and the patient

TOTAL (n = 85)	Surgeon (yes/no)	Patient (yes/no)	κ
Hematoma	60/25	35/50	0.031
Local pain	63/22	26/56	0.061
Arm pain	17/68	9/79	0.196
<b>Skin laceration</b>	17/68	21/64	<b>0.257</b>
Allergic reaction	29/56	0/85	0.000

## CONCLUSIONS

Patients and physicians differ in their evaluation of adverse events due to CCH treatment in Dupuytren's disease

The concordance of what is perceived as a secondary effect after infiltration with CCH between the patient and the surgeon is nil